Abbott Laboratories– tag –
-
MIT’s Non-Invasive Raman-Based CGM Achieves Accuracy Comparable to Commercial Devices, Signaling Next-Generation Glucose Monitoring Potential
Morld USA Overview MIT researchers have developed a novel Raman-based non-invasive continuous glucose monitoring (CGM) device that reads glucose through the skin without needles. Initial tests demonstrate accuracy comparable to existing ... -
Withings Introduces Abbott’s Lingo Biosensor for Non-Invasive Glucose Management, Targeting 70-140 mg/dL Range
Withings France Overview Withings introduces Abbott's Lingo as a non-invasive continuous glucose monitor (CGM) biosensor. Lingo painlessly attaches to the upper arm, streaming real-time glucose data to the Lingo app. This allows users to... -
diaTribe.org Recommends 6 Wearable Devices for Diabetes Management, Featuring Apple Watch & Samsung Galaxy Watch Integration
diaTribe.org USA Overview diaTribe.org has highlighted six wearable devices, including Apple Watch, Samsung Galaxy Watch, Google Pixel Watch, and Garmin Watch, that enhance diabetes management. These devices integrate with CGM systems li... -
Dexcom’s Stelo Achieves OTC Approval, Leading CGM Market for Non-Insulin Type 2 Diabetes Patients
CNET USA Overview Dexcom's Stelo has received FDA over-the-counter (OTC) approval, establishing it as a market leader in continuous glucose monitoring (CGM) for non-insulin users with Type 2 diabetes. The device provides real-time glucos... -
Consumer Smartwatch Technology in Health and Performance Research: Validity, Limitations, and the Challenge of Non-Invasive Glucose Sensing Highlighted
MDPI Switzerland Overview This review examines the validity, limitations, and real-world applications of consumer smartwatch technology in health and performance research, emphasizing the need for stronger validation and standardized dat... -
Medtronic Introduces Instinct Sensor, Expands MiniMed 780G System to Type 2 Diabetes with Dual FDA Clearances
Simply Wall St USA Overview Medtronic has expanded its diabetes sensor portfolio with the launch of the Instinct sensor, complementing its Simplera Sync™ and Guardian™ 4 sensors. The company also secured two key U.S. FDA regulatory miles... -
Advances and Challenges in Wearable Sensors: Non-Invasive Monitoring and AI Integration Revolutionize Health Management
ACS Publications USA Overview This mega-review explores the state-of-the-art in wearable (bio)sensors for health monitoring, emphasizing the shift towards continuous, non- or minimally invasive measurements of bodily fluids like sweat, s... -
Wireless Wearable Biosensors Advance Real-Time Health Monitoring: Capabilities and Challenges Explored
AZoLifeSciences Unknown Overview This article discusses the rapid advancements in wireless, battery-free wearable biosensors for continuous health monitoring. These devices track physiological signals and biomarkers like glucose, lactate... -
Dexcom G7 15-Day Continuous Glucose Monitor Authorized by Health Canada, Stelo CGM Cleared for Pediatric OTC Use by U.S. FDA
Business Wire, MarketScreener, CureCapture, Oura Member Care USA, Canada Overview Dexcom's G7 15-day continuous glucose monitoring (CGM) system has received Health Canada authorization for adults aged 18 and older, extending wear time to... -
Dexcom Stelo Secures First FDA OTC CGM Approval, Abbott Advances Freestyle Libre 3 Plus with 15-Day Wear & AID Compatibility
CNET USA Overview Dexcom's Stelo achieved the first FDA approval for an over-the-counter Continuous Glucose Monitor (CGM) in 2024, significantly broadening access for general consumers. Concurrently, Abbott's Freestyle Libre 3 Plus enter...
